SI3237416T1 - Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba - Google Patents
Policiklične spojine karbamoilpiridona in njihova farmacevtska uporabaInfo
- Publication number
- SI3237416T1 SI3237416T1 SI201530743T SI201530743T SI3237416T1 SI 3237416 T1 SI3237416 T1 SI 3237416T1 SI 201530743 T SI201530743 T SI 201530743T SI 201530743 T SI201530743 T SI 201530743T SI 3237416 T1 SI3237416 T1 SI 3237416T1
- Authority
- SI
- Slovenia
- Prior art keywords
- polycyclic
- pharmaceutical use
- carbamoylpyridone compounds
- carbamoylpyridone
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462096291P | 2014-12-23 | 2014-12-23 | |
EP15825729.5A EP3237416B1 (en) | 2014-12-23 | 2015-12-21 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
PCT/US2015/067155 WO2016106237A1 (en) | 2014-12-23 | 2015-12-21 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3237416T1 true SI3237416T1 (sl) | 2019-06-28 |
Family
ID=55168426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201530743T SI3237416T1 (sl) | 2014-12-23 | 2015-12-21 | Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba |
Country Status (24)
Country | Link |
---|---|
US (4) | US9522912B2 (sl) |
EP (2) | EP3237416B1 (sl) |
JP (3) | JP6393835B2 (sl) |
KR (4) | KR101978167B1 (sl) |
CN (2) | CN111454273A (sl) |
AR (1) | AR103251A1 (sl) |
AU (3) | AU2015369817B2 (sl) |
BR (1) | BR102015032109A2 (sl) |
CA (1) | CA2969244C (sl) |
EA (1) | EA201791019A1 (sl) |
ES (1) | ES2732482T3 (sl) |
HK (1) | HK1244000B (sl) |
IL (1) | IL252532A0 (sl) |
MA (1) | MA45613A (sl) |
MX (1) | MX2017007814A (sl) |
NZ (1) | NZ732391A (sl) |
PL (1) | PL3237416T3 (sl) |
PT (1) | PT3237416T (sl) |
SG (1) | SG11201704421QA (sl) |
SI (1) | SI3237416T1 (sl) |
TR (1) | TR201909152T4 (sl) |
TW (2) | TWI738321B (sl) |
UY (1) | UY36465A (sl) |
WO (1) | WO2016106237A1 (sl) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY164352A (en) | 2012-12-21 | 2017-12-15 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
HUE056470T2 (hu) | 2014-12-26 | 2022-02-28 | Univ Emory | Vírusellenes N4-Hidroxicitidin származékok |
CN107531727B (zh) * | 2015-04-02 | 2019-11-29 | 吉利德科学公司 | 多环氨甲酰基吡啶酮化合物及其药物用途 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
CN112218851A (zh) * | 2017-11-02 | 2021-01-12 | 卡里科生命科学有限责任公司 | 整合应激通路的调节剂 |
US11939320B2 (en) | 2017-11-02 | 2024-03-26 | Abbvie Inc. | Modulators of the integrated stress pathway |
GB2590198B (en) | 2017-12-07 | 2022-02-23 | Univ Emory | N4-hydroxycytidine derivatives and anti-viral uses related thereto |
WO2019113419A1 (en) * | 2017-12-08 | 2019-06-13 | The Rockefeller University | Pyrano[3,4-b]pyrazine kappa opioid receptor ligands for treating addiction, pruritus, pain, and inflammation |
PE20201414A1 (es) | 2018-05-31 | 2020-12-07 | Shionogi & Co | Derivado policiclico de piridona |
MX2020012176A (es) | 2018-05-31 | 2021-01-29 | Shionogi & Co | Derivado policiclico de carbamoilpiridona. |
MX2021011394A (es) | 2019-03-22 | 2021-10-13 | Gilead Sciences Inc | Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico. |
WO2021093846A1 (zh) * | 2019-11-13 | 2021-05-20 | 上海拓界生物医药科技有限公司 | 新型四环杂环化合物及其药物用途 |
JPWO2021107065A1 (sl) * | 2019-11-28 | 2021-06-03 | ||
US20230059640A1 (en) * | 2019-11-28 | 2023-02-23 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent |
WO2021173522A1 (en) | 2020-02-24 | 2021-09-02 | Gilead Sciences, Inc. | Tetracyclic compounds for treating hiv infection |
LT4196479T (lt) | 2021-01-19 | 2023-12-11 | Gilead Sciences, Inc. | Pakeistieji piridotriazino junginiai ir jų panaudojimo būdai |
CN114736173B (zh) * | 2022-05-24 | 2024-06-11 | 无锡捷化医药科技有限公司 | 一种3-(二氟甲基)氧杂环丁烷-3-胺盐酸盐的制备方法 |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US6642245B1 (en) | 1990-02-01 | 2003-11-04 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
GB2345058A (en) | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
CA2353961A1 (en) | 1998-12-25 | 2000-07-06 | Shionogi & Co., Ltd. | Heteroaromatic derivatives having an inhibitory activity against hiv integrase |
EP1297834A4 (en) | 2000-06-14 | 2007-05-09 | Shionogi & Co | ENZYME INHIBITOR HAVING TWO DIVALENT METAL IONS AS ACTIVE CENTERS |
EP2266958B1 (en) | 2001-08-10 | 2017-03-15 | Shionogi & Co., Ltd. | Antiviral agent |
CZ2004442A3 (cs) | 2001-10-03 | 2005-03-16 | Ucb, S.A. | Pyrrolidinonové deriváty |
ME00427B (me) | 2001-10-26 | 2011-10-10 | Msd Italia Srl | N-supstituisani hidroksipiramidinon karboksamidni inhibitori hiv integraze |
AU2003248872A1 (en) | 2002-07-09 | 2004-01-23 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
CA2498111A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
ATE443048T1 (de) | 2002-11-20 | 2009-10-15 | Japan Tobacco Inc | 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren |
MXPA05005448A (es) * | 2002-11-26 | 2005-08-26 | Ambient Corp | Arreglo de un acoplador inductivo para comunicacion de linea de alimentacion. |
US20060246130A1 (en) | 2003-01-14 | 2006-11-02 | Dahl Terrence C | Compositions and methods for combination antiviral therapy |
ATE490788T1 (de) | 2003-04-25 | 2010-12-15 | Gilead Sciences Inc | Antivirale phosphonate analoge |
TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
JP2007519735A (ja) | 2004-01-30 | 2007-07-19 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害剤として有用であるn−ベンジル−3,4−ジヒドロキシピリジン−2−カルボキサミド及びn−ベンジル−2,3−ジヒドロキシピリジン−4−カルボキサミド化合物 |
CN101014574A (zh) | 2004-03-09 | 2007-08-08 | 默克公司 | Hiv整合酶抑制剂 |
WO2005110414A2 (en) | 2004-05-07 | 2005-11-24 | Merck & Co., Inc. | Hiv integrase inhibitors |
US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
WO2005113509A1 (en) | 2004-05-20 | 2005-12-01 | Japan Tobacco Inc. | Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
WO2005112930A1 (en) | 2004-05-21 | 2005-12-01 | Japan Tobacco Inc. | Combinations comprising a 4-isoquinolone derivative and anti-hiv agents |
DE602005027466D1 (de) | 2004-07-27 | 2011-05-26 | Gilead Sciences Inc | Nukleosid phosphonat konjugate als anti hiv mittel |
WO2006030807A1 (ja) | 2004-09-15 | 2006-03-23 | Shionogi & Co., Ltd. | Hivインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体 |
WO2006066414A1 (en) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
JP5317257B2 (ja) | 2005-02-21 | 2013-10-16 | 塩野義製薬株式会社 | Hivインテグラーゼ阻害活性を有する2環性カルバモイルピリドン誘導体 |
SI3045206T1 (sl) | 2005-04-28 | 2018-07-31 | Viiv Healthcare Company | Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo |
US20060249072A1 (en) * | 2005-05-05 | 2006-11-09 | Csillag Frank J | Method of synthesizing a fluoride growth material for improved outgassing |
TW200716632A (en) | 2005-05-16 | 2007-05-01 | Gilead Sciences Inc | Integrase inhibitor compounds |
WO2007014352A2 (en) | 2005-07-27 | 2007-02-01 | Gilead Sciences, Inc. | Antiviral phosphonate conjugates for inhibition of hiv |
BRPI0617842A2 (pt) | 2005-10-27 | 2011-08-09 | Shionogi & Co | composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica |
CA2847871C (en) | 2005-12-30 | 2016-07-26 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
EP2452682A1 (en) | 2006-02-01 | 2012-05-16 | Japan Tobacco, Inc. | Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection |
NZ570706A (en) | 2006-03-06 | 2010-08-27 | Japan Tobacco Inc | Methods for producing an 4-oxoquinoline compound |
WO2007102499A1 (ja) | 2006-03-06 | 2007-09-13 | Japan Tobacco Inc. | 4-オキソキノリン化合物の製造方法 |
US7893055B2 (en) * | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
MX2009000661A (es) | 2006-07-19 | 2009-03-27 | Univ Georgia Res Found | Piridinon-diceto-acidos: inhibidores de replicacion de vih en terapia de combinacion. |
ES2536923T3 (es) | 2006-09-12 | 2015-05-29 | Gilead Sciences, Inc. | Proceso e intermedios para preparar inhibidores de la integrasa del VIH |
CA2665538A1 (en) | 2006-10-18 | 2008-04-24 | Merck & Co., Inc. | Hiv integrase inhibitors |
AU2008218186C1 (en) | 2007-02-23 | 2014-07-17 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US20080280945A1 (en) | 2007-05-09 | 2008-11-13 | Sachin Lohani | Crystalline forms of an HIV integrase inhibitor |
AR067184A1 (es) | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica |
BRPI0813000A2 (pt) | 2007-06-29 | 2014-12-23 | Gilead Sciences Inc | Composições terapêuticas e uso das mesmas |
US20090012103A1 (en) * | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
WO2009062285A1 (en) | 2007-11-16 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US20100272811A1 (en) | 2008-07-23 | 2010-10-28 | Alkermes,Inc. | Complex of trospium and pharmaceutical compositions thereof |
WO2010011815A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
EP2320908B9 (en) | 2008-07-25 | 2014-06-18 | VIIV Healthcare Company | Dolutegravir Prodrugs |
ES2449752T3 (es) | 2008-07-25 | 2014-03-21 | Viiv Healthcare Company | Proceso para la preparación de un derivado de pirido[1,2-a]pirrolo[1',2':3,4]imidazo[1,2-d]piracin-8-carboxamida |
PT2660239T (pt) * | 2008-07-25 | 2017-02-24 | Shionogi & Co | Compostos químicos como intermediários sintéticos |
WO2010011819A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
WO2010011818A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
CN102245182B (zh) | 2008-12-11 | 2014-07-23 | 盐野义制药株式会社 | 氨基甲酰基吡啶酮hiv整合酶抑制剂和中间体的合成 |
JP2012512246A (ja) * | 2008-12-17 | 2012-05-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | C環修飾型三環式ベンゾナフチリジノン・タンパク質キナーゼ阻害薬及びこれらの使用 |
TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
ES2670811T3 (es) | 2010-01-27 | 2018-06-01 | Viiv Healthcare Company | Terapia antivírica |
EP2540720B1 (en) | 2010-02-26 | 2015-04-15 | Japan Tobacco, Inc. | 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor |
TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Viiv醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
US20130165489A1 (en) | 2010-05-03 | 2013-06-27 | The Trustees Of The University Of Pennsylvania | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
PT2588450T (pt) | 2010-07-02 | 2017-08-03 | Gilead Sciences Inc | Derivados do ácido naft-2-ilacético para tratamento da sida |
PE20130525A1 (es) | 2010-07-02 | 2013-05-05 | Gilead Sciences Inc | Derivados de acido 2 quinolinil acetico como compuestos antivirales frente a vih |
HUE054473T2 (hu) | 2010-08-05 | 2021-09-28 | Shionogi & Co | Eljárás HIV-integráz inhibitor hatású vegyületek elõállítására |
MX2013003139A (es) | 2010-09-24 | 2013-06-18 | Shionogi & Co | Profarmaco de derivado de carbamoilpiridona policiclica substituida. |
EP2699558B1 (en) | 2011-04-21 | 2016-11-23 | Gilead Sciences, Inc. | Benzothiazole compounds and their pharmaceutical use |
US20140213553A1 (en) | 2011-05-03 | 2014-07-31 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
WO2012151567A1 (en) | 2011-05-05 | 2012-11-08 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for preventing and treating influenza |
US9540343B2 (en) | 2011-07-06 | 2017-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
US9206197B2 (en) | 2011-09-14 | 2015-12-08 | Mapi Pharma Ltd. | Amorphous form of dolutegravir |
CN103974957A (zh) | 2011-10-12 | 2014-08-06 | 盐野义制药株式会社 | 具有整合酶抑制活性的多环吡啶酮衍生物 |
US9399645B2 (en) | 2011-12-20 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Inhibitors of HIV replication |
WO2013103738A1 (en) * | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | Napthalene acetic acid derivatives against hiv infection |
WO2013159064A1 (en) | 2012-04-20 | 2013-10-24 | Gilead Sciences, Inc. | Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection |
WO2014008636A1 (en) | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
EP2875024A4 (en) | 2012-07-20 | 2015-12-23 | Merck Sharp & Dohme | HIV TREATMENT WITH AMIDOSUBSTITUTED PYRIMIDINONE DERIVATIVES |
US20150218164A1 (en) | 2012-07-25 | 2015-08-06 | Merck Sharp & Dohme Corp. | Substituted naphthyridinedione derivatives as hiv integrase inhibitors |
WO2014022707A1 (en) | 2012-08-03 | 2014-02-06 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
CA2893959A1 (en) | 2012-12-14 | 2014-06-19 | Shenshen Cai | Pharmaceutical compositions |
EP2931730B1 (en) * | 2012-12-17 | 2019-08-07 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as hiv integrase inhibitors |
MY164352A (en) * | 2012-12-21 | 2017-12-15 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
US20140221355A1 (en) | 2012-12-21 | 2014-08-07 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
WO2014100077A1 (en) | 2012-12-21 | 2014-06-26 | Merck Sharp & Dohme Corp. | Gastro-retentive formulations |
MX2015008467A (es) | 2012-12-27 | 2015-09-23 | Japan Tobacco Inc | Derivado sustituido de espiropirido[1,2-a]pirazina y uso medico del mismo como inhibidor de la integrasa del virus de inmunodeficiencia humana. |
EP2986291B1 (en) * | 2013-04-16 | 2020-05-27 | Merck Sharp & Dohme Corp. | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors |
US9951079B2 (en) * | 2013-06-13 | 2018-04-24 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors |
WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
SG11201602217XA (en) | 2013-09-27 | 2016-04-28 | Merck Sharp & Dohme | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
CN107531727B (zh) * | 2015-04-02 | 2019-11-29 | 吉利德科学公司 | 多环氨甲酰基吡啶酮化合物及其药物用途 |
-
2015
- 2015-12-10 TW TW109115099A patent/TWI738321B/zh active
- 2015-12-10 TW TW104141539A patent/TWI695003B/zh active
- 2015-12-21 EP EP15825729.5A patent/EP3237416B1/en active Active
- 2015-12-21 TR TR2019/09152T patent/TR201909152T4/tr unknown
- 2015-12-21 KR KR1020177020150A patent/KR101978167B1/ko active IP Right Grant
- 2015-12-21 NZ NZ732391A patent/NZ732391A/en not_active IP Right Cessation
- 2015-12-21 AU AU2015369817A patent/AU2015369817B2/en active Active
- 2015-12-21 EA EA201791019A patent/EA201791019A1/ru unknown
- 2015-12-21 CA CA2969244A patent/CA2969244C/en active Active
- 2015-12-21 KR KR1020197013162A patent/KR102020004B1/ko active IP Right Grant
- 2015-12-21 KR KR1020217010577A patent/KR20210042185A/ko not_active Application Discontinuation
- 2015-12-21 WO PCT/US2015/067155 patent/WO2016106237A1/en active Application Filing
- 2015-12-21 PT PT15825729T patent/PT3237416T/pt unknown
- 2015-12-21 SG SG11201704421QA patent/SG11201704421QA/en unknown
- 2015-12-21 JP JP2017531320A patent/JP6393835B2/ja active Active
- 2015-12-21 MA MA045613A patent/MA45613A/fr unknown
- 2015-12-21 CN CN202010421213.7A patent/CN111454273A/zh active Pending
- 2015-12-21 EP EP18173776.8A patent/EP3388431A1/en active Pending
- 2015-12-21 SI SI201530743T patent/SI3237416T1/sl unknown
- 2015-12-21 ES ES15825729T patent/ES2732482T3/es active Active
- 2015-12-21 BR BR102015032109A patent/BR102015032109A2/pt not_active Application Discontinuation
- 2015-12-21 US US14/977,347 patent/US9522912B2/en active Active
- 2015-12-21 MX MX2017007814A patent/MX2017007814A/es unknown
- 2015-12-21 UY UY0001036465A patent/UY36465A/es not_active Application Discontinuation
- 2015-12-21 CN CN201580070876.6A patent/CN107108643B/zh active Active
- 2015-12-21 KR KR1020197025726A patent/KR102240584B1/ko active IP Right Grant
- 2015-12-21 PL PL15825729T patent/PL3237416T3/pl unknown
- 2015-12-22 AR ARP150104261A patent/AR103251A1/es unknown
-
2016
- 2016-11-11 US US15/349,353 patent/US9795602B2/en active Active
-
2017
- 2017-05-25 IL IL252532A patent/IL252532A0/en unknown
- 2017-09-14 US US15/704,842 patent/US10646486B2/en active Active
-
2018
- 2018-03-12 HK HK18103442.8A patent/HK1244000B/zh unknown
- 2018-07-20 JP JP2018136915A patent/JP6934846B2/ja active Active
-
2019
- 2019-01-22 AU AU2019200422A patent/AU2019200422B2/en active Active
-
2020
- 2020-01-07 JP JP2020000897A patent/JP2020073560A/ja active Pending
- 2020-03-27 US US16/832,230 patent/US20210015816A1/en not_active Abandoned
- 2020-12-10 AU AU2020286299A patent/AU2020286299B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1244000B (zh) | 多環氨基甲酰吡啶酮化合物及其藥物用途 | |
HK1249103B (zh) | 多環氨甲醯基吡啶酮化合物及其藥物用途 | |
HK1243073A1 (zh) | 治療性化合物及其用途 | |
GB201403093D0 (en) | Therapeutic compounds and their use | |
IL283335B (en) | Dihydropyrimidine-2-one compounds and their medical use | |
HK1232211A1 (zh) | 二甲基吡啶胺衍生物及其醫藥用途 | |
ZA201701492B (en) | Pyrazolothiazole compound and medicine | |
GB201702464D0 (en) | Pharmaceutical agent | |
GB201406115D0 (en) | New pharmaceutical use | |
GB201517133D0 (en) | New pharmaceutical use | |
GB201409662D0 (en) | New pharmaceutical use | |
GB201616767D0 (en) | New pharmaceutical use | |
GB201517454D0 (en) | New pharmaceutical use | |
GB201517132D0 (en) | New pharmaceutical use | |
GB201508611D0 (en) | New pharmaceutical use | |
GB201508613D0 (en) | New pharmaceutical use | |
GB201507813D0 (en) | New pharmaceutical use | |
GB201410387D0 (en) | Compounds and their therapeutic use | |
GB201403496D0 (en) | Compounds and their therapeutic use | |
GB201413411D0 (en) | Novel compounds and their use |